ALS drug pulled from market in Canada, U.S. after failing late-stage clinical trial

  • 📰 CBCNews
  • ⏱ Reading Time:
  • 16 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 10%
  • Publisher: 99%

المملكة العربية السعودية أخبار أخبار

المملكة العربية السعودية أحدث الأخبار,المملكة العربية السعودية عناوين

Manitoba Possible provides long-term loans of manual and motorized wheelchairs to more than 14,000 people, along with repair, maintenance and modification services.

Amylyx Pharmaceuticals has announced it will withdraw its amyotrophic lateral sclerosis drug from the market in Canada and the U.S. following its failure in a late-stage clinical trial.An ALS drug branded Albrioza in Canada and Relyvrio in the U.S. failed to outperform a placebo on a scale that measures the ability of patients to perform tasks such as walking, Amylyx Pharmaceuticals said Thursday.

The medication is Amylyx's only product on the market. The drug will no longer be available to new patients. Approval followed a rare turnaround by the U.S. Food and Drug Administration's advisers. They backed the drug months after rejecting it for a lack of "substantially persuasive" data.

 

شكرًا لك على تعليقك. سيتم نشر تعليقك بعد مراجعته.
لقد قمنا بتلخيص هذا الخبر حتى تتمكن من قراءته بسرعة. إذا كنت مهتمًا بالأخبار، يمكنك قراءة النص الكامل هنا. اقرأ أكثر:

 /  🏆 2. in SA

المملكة العربية السعودية أحدث الأخبار, المملكة العربية السعودية عناوين